臨床薬理の進歩 No.43

64/233

＊0＊＊＊＊＊表1　非EBV関連腫瘍におけるMSIステータス別の臨床病理学的・分子生物学的特徴（N=363）MSI statusSexAge at surgery (y, mean ± SD)Year of surgeryBody mass index (kg/m2, mean ± SD) Tumor diameter (mm, mean ± SD) Siewert classificationBarrett's esophaguspT StagepN StageNo. of nodes harvested (mean ± SD)No. of metastatic nodes (mean ± SD)M stagepStageMSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSS, microsatellite stable.Clinicopathological featuresBefore Dec. 2009Jan. 2010 to Jan. 2015 ＜22.5 (median)≧22.5 (median)＜50 (median)≧50 (median)Total No.FemaleMale58 (16%)305 (84%)65.2 ± 12.4170 (47%)193 (53%)22.7 ± 3.4175 (49%)185 (51%)56.4 ± 30.7165 (45%)198 (55%)TypeⅠ52 (14%)TypeⅡ259 (72%)TypeⅢ52 (14%)AbsentPresent257 (71%)106 (29%)pT1pT2pT3pT480 (22%)53 (15%)132 (36%)98 (27%)pN0pN1pN2pN3134 (37%)76 (21%)61 (17%)92 (25%)35.3 ± 17.94.5 ± 6.8M0M1307 (85%)56 (15%)94 (26%)Ⅰ49 (14%)ⅡⅢ164 (45%)Ⅳ56 (15%)MSI-H(N=28)MSI-L(N=24)7 (25%)21 (75%)71.7 ± 11.34 (17%)20 (83%)62.7 ± 11.814 (50%)14 (50%)23.1 ± 3.211 (39%)17 (61%)62.9 ± 37.911 (39%)17 (61%)16 (67%)8 (33%)22.6 ± 3.59 (39%)14 (61%)50.0 ± 28.013 (54%)11 (46%)4 (17%)15 (62%)5 (21%)22 (79%)6 (21%)21 (75%)7 (25%)18 (75%)6 (25%)7 (25%)4 (14%)11 (40%)6 (21%)6 (25%)5 (21%)8 (33%)5 (21%)18 (64%)5 (18%)4 (14%)1 (4%)11 (46%)5 (21%)5 (21%)3 (13%)35.0 ± 14.82.3 ± 3.235.3 ± 19.51.5 ± 3.427 (96%)1 (4%)22 (92%)2 (8%)10 (35%)8 (29%)9 (32%)1 (4%)7 (29%)5 (21%)10 (42%)2 (8%)p (across 3 MSI status)MSS(N=311)0.3947 (15%)264 (85%)64.8 ± 12.30.0070.12140 (45%)171 (55%)22.6 ± 3.5155 (50%)154 (50%)56.3 ± 30.2141 (45%)170 (55%)0.800.350.440.560.1548 (15%)222 (72%)41 (13%)0.77218 (70%)93 (30%)0.9467 (22%)44 (14%)113 (36%)87 (28%)0.018105 (34%)66 (21%)52 (17%)88 (28%)35.3 ± 18.05.0 ± 7.20.920.00120.10258 (83%)53 (17%)0.04477 (25%)36 (12%)145 (46%)53 (17%)50